Automated and Closed Cell Therapy Processing Systems Markets, 2030 – PRNewswire

DUBLIN, April 6, 2021 /PRNewswire/ -- The "Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps, Scale of Operations, End Users and Geographical Regions: Industry Trends and Global Forecasts, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.

The "Automated and Closed Cell Therapy Processing Systems Market: Focus on Apheresis, Expansion, Harvest, Fill/Finish, Cryopreservation, Thawing, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the automated and closed cell therapy processing systems. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

One of the key objectives of the report was to estimate the existing market size and the future growth potential of the automated and closed cell therapy processing systems. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the period 2020-2030.

Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies.

However, despite the numerous advances in this field, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing), thereby, rendering the processes difficult to scale-up, with high risk of contamination.

Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose.

Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality.

Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation), has effectively captured the interest of several stakeholders engaged in this domain. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant growth in the foreseen future.

Key Questions Answered

Key Topics Covered:

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Cell Therapies3.3. Cell Therapy Manufacturing3.4. Key Challenges Associated with Manufacturing Cell Therapies3.5. Overview of Automated and Closed Cell Processing Systems3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing3.5.2. Advantages and Affiliated Challenges3.6. Key Growth Drivers and Roadblocks3.7. Recent Developments and Upcoming Trends

4. COMPETITIVE LANDSCAPE4.1. Chapter Overview4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape

5. PRODUCT COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Assumptions/Key Parameters5.3. Methodology5.4. Product Competitiveness Analysis

6. COMPANY PROFILES6.1 Chapter Overview6.2 Cytiva6.3. Pall6.4. Terumo BCT6.5 ThermoGenesis

7. PARTNERSHIPS7.1 Chapter Overview7.2. Partnership Models7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships

8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN8.1. Chapter Overview8.2. Initiatives Undertaken by Big Pharma Players8.2.1. Initiatives Undertaken by AbbVie8.2.2. Initiatives Undertaken by Bristol Myers Squibb8.2.3. Initiatives Undertaken by Gilead Sciences8.2.4. Initiatives Undertaken by GlaxoSmithKline8.2.5. Initiatives Undertaken by Johnson & Johnson8.2.6. Initiatives Undertaken by Novartis8.2.7. Initiatives Undertaken by Roche8.2.8. Initiatives Undertaken by Sanofi8.2.9. Initiatives Undertaken by Takeda Pharmaceutical8.2.10. Summary of Big Pharma Initiatives

9. LIKELY PARTNER9.1. Chapter Overview9.2. Scope and Methodology9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development9.3.1. Dendritic Cell Therapy9.3.2. Stem Cell Therapy9.3.3. T-cell Therapy9.3.4. Natural Killer Cell Therapy9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing9.4.1. Dendritic Cell Therapy9.4.2. Stem Cell Therapy,9.4.3. T-cell Therapy9.4.4. Natural Killer Cell Therapy

10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS10.1. Chapter Overview10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems10.3. Likely Cost Saving Potential for Kymriah10.4. Likely Cost Saving Potential for Yescarata10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS11.1. Chapter Overview11.2. Key Assumptions and Methodology11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030

12. CONCLUSION12.1. Chapter Overview12.2. Key Takeaways

13. INTERVIEW/SURVEY TRANSCRIPT(S)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/3e1u4o

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more:

Automated and Closed Cell Therapy Processing Systems Markets, 2030 - PRNewswire